Literature DB >> 3103439

Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis.

J M Jordan, N B Allen, S V Pizzo.   

Abstract

The fibrinolytic system in a group of 23 patients with vasculitis and 10 patients with the cutaneous vasculitis atrophie blanche were studied. These patients were found to have markedly suppressed release of vascular tissue plasminogen activator (t-PA) stores whether the disease was active or in remission. The control group had releasable t-PA levels of 0.70 +/- 0.10 IU/ml of plasma. Levels of releasable t-PA in the patient population were 0.09 +/- 0.03 IU/ml for those with active vasculitis (p less than 0.0001 compared with the control group by the Student t test), 0.23 +/- 0.12 IU/ml for those with inactive vasculitis (p less than 0.001), and 0.03 +/- 0.01 IU/ml for those with atrophie blanche (p less than 0.0001). It is concluded that there is a generalized defect in plasminogen activator in a variety of vasculitides. Such a defect may contribute to the pathogenesis of lesions as well as the thromboembolic disease that may be observed in these patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3103439     DOI: 10.1016/0002-9343(87)90436-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

1.  Behçet's disease with a large intracardiac thrombus: a case report.

Authors:  M Baykan; S Celik; C Erdöl; E C Baykan; I Durmus; S Bahadir; H Erdöl; C Orem; H Cakirbay
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

2.  Endothelial cell derived factors in relation to antibodies to SSA or SSB and to endothelial cells in Sjögren's syndrome.

Authors:  S Rantapää-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

3.  Cardiac thrombosis in a patient with Behçet's disease: two years follow-up.

Authors:  Y Basaran; M Degertekin; H Direskeneli; C Yakut
Journal:  Int J Card Imaging       Date:  2000-10

4.  von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis.

Authors:  E Nordborg; R Andersson; L Tengborn; S Edén; B A Bengtsson
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

5.  Cardiovascular Involvement in Behçet Disease: Clinical Implications.

Authors:  Malka Yahalom; Lev Bloch; Khaled Suleiman; Bar Rosh; Yoav Turgeman
Journal:  Int J Angiol       Date:  2015-06-05

6.  Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis.

Authors:  S Wållberg-Jonsson; G H Dahlén; T K Nilsson; M Rånby; S Rantapää-Dahlqvist
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

7.  Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy.

Authors:  A Doria; A Ghirardello; M Boscaro; M L Viero; E Vaccaro; G M Patrassi; P F Gambari
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

8.  Intracardiac thrombus in Behçet's disease: two case reports.

Authors:  Sonia Hammami; Silvia Mahjoub; Khaldoun Ben-Hamda; Radhia Brahem; Habib Gamra; Mohamed Ben Farhat
Journal:  Thromb J       Date:  2005-07-25

Review 9.  Complement Activation in Inflammatory Skin Diseases.

Authors:  Jenny Giang; Marc A J Seelen; Martijn B A van Doorn; Robert Rissmann; Errol P Prens; Jeffrey Damman
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

10.  Alu DNA Polymorphism of Human Tissue Plasminogen Activator (tPA) Gene in Diabetic Jordanian Patients

Authors:  Salem R. Yasin; Hussam H. AlHawari; Abeer A. Alassaf; Maysa M. Khadra; Zainab A. Al-Mazaydeh; Ala'a F. Al-Emerieen; Lubna H. Tahtamouni
Journal:  Iran Biomed J       Date:  2019-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.